Beta Bionics and Senseonics Collaborate on AI-Driven Pancreas

Just a few weeks after Beta Bionics made headlines with an IDE approval for its artificial intelligence (AI) driven iLet bionic pancreas system, the company is in the spotlight again. This time, Beta Bionics is teaming up with Senseonics Holdings, a company that is developing an implantable continuous glucose monitoring (CGM) system. Under this agreement, Beta Bionics will integrate Germantown, MD-based Senseonics’ Eversense CGM system with the iLet. Real-time data generated by Eversense could serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system. The iLet consists of a dual-chamber, autonomous, infusion pump that mimics a biological pancreas. The body-worn device contains a little cartridge with insulin in it. The device is connected to the body through a tube with insulin. There is also a two-hormone version of the technology, so it can be configured to use insulin or glucagon. Embedded in the system are clinically tested mathematical dosing algorithms driven by machine learning to autonomously calculate and dose insulin and/or glucagon as needed, based on data from a CGM. Once initialized, the iLet engages its machine-learning, AI to autonomously control the individual’s blood-glucose levels, and to continuously adapt to the individual’s ever-changing insulin needs. The Eversense CGM system is a long-term, implantable CGM that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone applicati...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Digital Health Source Type: news